AllDocs -> cancers

ovarian cancer Ovarian Cancer Amreen Husain, MD Assistant Professor Gynecologic Oncology Ovarian cancer 25,000 cases annually 1/70 American women 14,000 deaths annually 4th in cancer related deaths among women Mean age at diagnosis 59 yrs Risk factors Family history: One 1° relative 3.6 times risk, or 5% lifetime risk. 5- 10% of all ovarian cancers associated with known gene mutations. Three familial ovarian cancer syndromes: site-specific ovarian cancer , breast/ ovarian cancer syndrome, hereditary nonpolyposis colorectal cancer syndrome. BRCA1/2 Associated with site specific and breast/ ovarian cancer syndromes. BRCA1: 25-40% lifetime risk of Ov ca, 80% lifetime risk of Breast Ca BRCA2 : 10% lifetime risk of ov Ca Early age-onset, 10yrs ...

Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - October 2003 Page 2 2 S S C C I I E E N N T T I I F F I I C C B B A A C C K K G G R R O O U U N N D D Breast cancer is considered to be one of the most prevalent cancer in women. The overall frequency of breast cancer has increased in Europe, with a particularly tremendous increase over the past 20 years among younger women. However, the mortality rate for this cancer has decreased over the last 6 years. In Germany there are about 45.000 new cases of breast cancer being reported each year, approximately 18.000 women die due ...

REPORT OF THE OVARIAN CANCER WORKSHOP Improving outcomes for Australian women with ovarian cancer 28 th September 2001 Melbourne a collaborative initiative of the National Cancer Control Initiative, the Commonwealth Department of Health and Aged Care, the iSource National Breast Cancer Centre and OvCa Australia. Report prepared by the iSource National Breast Cancer Centre on behalf of the Workshop Steering Committee Page 2 2 1.0 Background: Each year in Australia, about 1200 women are diagnosed with ovarian cancer and about 800 women will die from the disease. Ovarian cancer is the leading cause of death from gynaecological cancers and the sixth most common cause of cancer death in Australian women. About 1 in 70 Australian ...

Priority actions for ovarian cancer control: a framework for a national approach. April 2002 Page 2 P r i o r i ty a c t ion s f or o va r ian ca n ce r co n tr o l : a f ra m ewo r k f o r a n at io na l a pp r oa ch 1 Foreword Ovarian cancer is the leading cause of death from gynaecological cancers in Australia. Health care professionals and consumers have identified a number of opportunities for improvement in ovarian cancer control. Priority actions for ovarian cancer control: a framework for a national approach was developed by the National Breast Cancer Centre following an extensive process of consultation with over 50 key stakeholders across Australia. It identifies a number of priority actions which are seen as being important for ovarian cancer control. This document is presented ...

O v a r i a n c a n c e r I n Au s t r a l i a n wo m e n 1 Ovarian cancer in Australian women Anne Kricker National Ovarian Cancer Centre February 2002 Page 2 2 Acknowledgements We would like to thank Professor Bruce Armstrong, Professor Neville Hacker, Dr Ian Hammond, Dr David Roder and Ms Elizabeth Tracey for reviewing a draft of this report. Page 3 O v a r i a n c a n c e r I n Au s t r a l i a n wo m e n 3 Contents Impact of ovarian cancer in Australian women 5 Incidence and mortality in Australian women 8 Age-specific incidence and mortality 9 Incidence and mortality trends in 1983-1998 10 Commonly occurring cancers in 1998 11 Most commonly occurring cancers in Australian women in 1998 12 Estimated ...

Jeanne M. Wallace, Ph.D., C.N.C. Nutritional Solutions, Inc., North Logan UT eMail: nutritionalsolutions@comcast.net Web: www.nutritional-solutions.net Expanding the Model of Cancer Treatment: How Diet & Nutrition Can Help Control Ovarian Cancer Page 2 The Role of Diet and Nutrition Foundation Support - heal whole person: body/mind/spirit Complement Treatment - surgery, radiation, chemotherapy, immunotherapy Biologic Response Modifiers - target vulnerable molecular pathways to help “control” cancer Biologic Response Modifiers Page 3 Targets for Cancer Control Regulate gene expression (down-regulate oncogenes) Block “grow” messages (e.g., inflammatory compounds) Inhibit angiogenesis—the development of new blood vessels that ...

OVARIAN CANCER AWARENESS MONTH WHEREAS: Ovarian cancer has long been called a “silent killer,” because it occurs in an organ deep in the pelvis and produces vague symptoms that may be dismissed; and WHEREAS: Recent studies have identified factors that put women at higher risk of developing ovarian cancer , such as a family history of breast and ovarian cancer , no pregnancies or infertility, no history of oral contraceptive use, or the use of high-dose estrogen for long periods without progesterone; and WHEREAS: Early detection remains the most valuable weapon against ovarian cancer ; however, there is not a simple early detection method. Subtle symptoms include pelvic and abdominal pressure; bloating; pain, swelling or discomfort; unexpected weight gain or loss, especially weight gain in the abdominal area; gastrointestinal problems; and ...

126 Title 3—The President Proc. 7587 Proclamation 7587 of August 30, 2002 National Ovarian Cancer Awareness Month, 2002 By the President of the United States of America A Proclamation During National Ovarian Cancer Awareness Month, Americans renew their commitment to learning more about the causes of this deadly disease, so that we can detect it early and treat it effectively. Ovarian cancer continues to cause more deaths than any other cancer of the female reproductive system. It is estimated that this year alone, more than 23,000 women in the United States will be diagnosed with ovarian cancer , and that almost 14,000 women will die from this disease. In cases where ovarian cancer is found and treated in its earliest stages, the 5-year survival rate is 95 percent. However, most women who suffer from this cancer are ...

Participating Ovarian Cancer Survivors, Friends, Families and Co-operating Cancer Centres Participants includes ovarian cancer survivors, daughters, friends and families and many more persons who are so generously giving of their time and compassion Co-operating Cancer Centres click on links below to take you direct to the Cancer Centre/Foundation for donation information - either on-line or by telephone - ***Note: you will need to indicate the donation is for: Dare to Dream for Ovarian Cancer Barbara Armstrong (on vacation) Laura Walsh Susan Z. Martin Susan MacKenzie Note: all B.C. donations: click below to go to on-line donating ? Events: type in 'Dare to Dream for Ovarian Cancer ' ? indicate the ...

TO ALL ASSIGNMENT EDITORS/HEALTH EDITORS September 2, 2003 September is National Ovarian Cancer Awareness Month (Toronto) – Most women don’t know that the Pap smear test does not detect ovarian cancer . In fact, most women don’t know that a single early detection test for ovarian cancer does not exist. The National Ovarian Cancer Association’s (NOCA) goal is to raise awareness about the signs and symptoms, to support women and their families who are living with ovarian cancer , and to be the source on ovarian cancer in Canada. Increasing knowledge and early detection are the best weapons against this horrible disease. “Over 2600 women are diagnosed with ovarian cancer every year – that is one in 70 women in Canada and it is the most serious gynecologic cancer largely because there is no single early detection test,” says Elisabeth ...

DARE TO DREAM for Ovarian Cancer http://www.daretodreamforovariancancer.ca COME AND MEET DEBORAH LANDRY ON FRIDAY SEPTEMBER 5, 2003 AT 12 NOON AT THE HAMILTON REGIONAL CANCER CENTRE, 699 CONCESSION STREET SHE WILL BE HERE TO RAISE AWARENESS AND DONATIONS FOR OVARIAN CANCER !! HEAR HER CROSS COUNTRY EXPERIENCES AND THE SUCCESSES SHE HAS HAD IN RAISING AWARENESS FOR THIS “SILENT KILLER”. Deborah will also be at Limeridge Mall: Friday September 5, 2003 from 5:00pm until 8:00pm Please Come and Join Us!! Deborah will complete her journey which began at the Princess Margaret Hospital on June 14/03 in Toronto the next day! Thank you for your support Dream with Us For further information please contact: Noreen Spraggon 905 388-1986 Or: Hamilton Regional Cancer Centre Foundation 905 575-6363 ...

Although twelve years have passed since the untimely death of comedy's pint-size dynamo, Gilda Radner's legacy as a victim of ovarian cancer has brought greater focus to this silent disease. Ovarian cancer is one of the most common forms of gynecologic malignancies. According t the American Cancer Society, it is the fourth most frequent cause of cancer death. This year alone, over 25,000 women will be diagnosed with the disease, and about 14,000 will die. There are three major types of ovarian cancer . The first is epithelial carcinoma, which arises from the cells covering the surface of the ovaries. This accounts for 80% of all ovarian cancer cases. The second is germ cell tumors, which develops in the eggs. This is usually seen in a young woman, and is unfortunately very aggressive and fast growing. This type is often fatal within one to two years. The third is ovarian stromal tumors, ...

1 Peer Reviewers FY99 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Ackerman, Virginia M. Ovarian Cancer National Alliance Alexander, Doreene W. Southern New Mexico Cancer Support Services, Inc. Ambrosone, Christine B. Ph.D. Division of Molecular Epidemiology, National Center for Toxicological Research, Federal Drug Administration Andre, Michael P. Ph.D. Department of Radiology, University of California at San Diego Armstrong, Deborah K. M.D. Department of Medical Oncology, Johns Hopkins Oncology Center Ascensao, Joao L. M.D., Ph.D. Department of Internal Medicine, University of Nevada School of Medicine Bourguignon, Lilly Y. W. Ph.D. Department of Cell Biology and Anatomy, University of Miami Medical School Boyd, Jeffrey A. Ph.D. ...

Peer Reviewers 1 FY00 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Artemov, Dmitri Ph.D. Department of Radiology, Division of Magnetic Resonance Research, The Johns Hopkins University School of Medicine Atwood, Jan R. Ph.D., M.P.H., R.N., F.A.A.N. University of Nebraska Medical Center Bachur, Nicholas R. M.D., Ph.D. Department of Medicine, University of Maryland Cancer Center Bandera, Christina A. M.D. Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine Beattie, Craig W. Ph.D. Department of Veterinary Medicine, University of Nevada, Reno Boothman, David A. Ph.D. Department of Radiation Oncology, Case Western Reserve University Boyd, Jeffrey A. Ph.D. Departments of Surgery and Human Genetics, Memorial Sloan- Kettering ...

FY02 Ovarian Cancer Research Program Peer Reviewers Bai, Wenlong Ph.D. Baron, Andre T. Ph.D. Biochemistry and Molecular Biology, Mayo Clinic Foundation Batra, Surinder K. Ph.D. Dept. of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beck, William T. Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris M. Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Bieberich, Charles J. Ph.D. Department of Biological Sciences, University of Maryland Baltimore County Bigbee, William L. Ph.D. Cancer Epidemiology Program, University of Pittsburgh Cancer Institute Blay, Jonathan Ph.D. Dept of Pharmacology, Dalhousie University Faculty of Medicine Bouhassira, Eric ...

FY01 Ovarian Cancer Research Program Peer Reviewers Almeida-Porada, Maria Graca D. M.D., Ph.D. Department of Medicine, VA Medical Center Bandera, Christina A. M.D. Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine Batra, Surinder Kumar Ph.D. Department of Biochemistry & Molecular Biology, University of Nebraska Medical College Beattie, Craig W. Ph.D. Department of Animal Biotechnology, University of Nevada- Reno Bigbee, William L. Ph.D. Dept. of Environmental & Occupational Health, University of Pittsburgh Cancer Institute Bourguignon, Lilly Y. W. Ph.D. VA Medical Center, University of California-San Francisco Boyd, Jeffrey A. Ph.D. Departments of Surgery and Human Genetics, Memorial Sloan Kettering Cancer Center Carney, James P. Ph.D. RORL, ...

FY98 Ovarian Cancer Research Program Peer Reviewers Peer Reviewer Degree Institution/Affiliation Ackerman, Virginia Consumer Alvarez, Ronald M.D. Department of Obstetrics/Gynecology, University of Alabama at Birmingham Artemov, Dmitri Ph.D. Department of Radiology, The Johns Hopkins University School of Medicine Barton, Michelle Ph.D. Department of Molecular Genetics, University of Cincinnati Berchuck, Andrew M.D. Duke University Medical Center Bernstein, Jonine Ph.D. Department of Community and Preventive Medicine, Mount Sinai School of Medicine Bienstock, Rachelle Ph.D. National Institute of Environmental Health Sciences Boothman, David Ph.D. Departments of Radiation Oncology and Pharmacology, Case Western Reserve University Braly, Patricia M.D. Department of Obstetrics and Gynecology, ...

A Cancer Genetics Network Study offered by: The Division of Gynecologic Oncology The Center for Medical Genetics Feinberg School of Medicine, Seeking A Better Way To Detect Ovarian Cancer This national study, funded by the National Cancer Institute, is part of a larger project called the Cancer Genetics Network. Evanston Northwestern Healthcare is one of more than a dozen regional centers across the United States that are participating in the study. The other centers include: Massachusetts General Hospital, M.D. Anderson Cancer Center, Johns Hopkins University. It is expected that 2,400 or more women from families with a history of breast and/or ovarian cancer will participate in this study. Women who enroll in the study may come to the hospital for their study-related visits, or they may use their own clinics or personal physicians. ...

Fox Chase Cancer Center 2002 Scientific Report Drug Resistance in Model Systems. Hamilton, Ozols, Selvakumaran, Williams, Bao, Bingham, Schoenberger The aggressive therapy of ovarian cancer includes, as a cornerstone, cisplatin or one of its analogs. Thus, our investigations of the mechanisms of drug resistance in ovarian can- cer cells primarily involve the study of mecha- nisms of platinum resistance. One approach we have used to study this problem has been to produce cisplatin-resistant ovarian cancer cell lines by exposure of drug sensitive cell lines to increasing concentrations of cisplatin. The most resistant of these variants, C200, is nearly 500-fold resistant to cisplatin. These cell lines show a complex cross-resistance phenotype typical of clinical ovarian cancer ; they are cross-resistant to carboplatin, tetraplatin, mel- phalan, ...

FERTILITY AND OVARIAN CANCER A study published in January 1993 in the American Journal of Epidemiology (136:1184-1203) has suggested a possible association between infertile women using drugs for ovulation induction and ovarian cancer . The study failed to specify, among other important information, the fertility drugs used by affected women. Nevertheless, it generated a lot of media attention and also raised concerns particularly among infertility patients with regard to the safety of the medications commonly prescribed by their physicians. The purpose of this communication is to clarify some of the points in the study that render it severely flawed in its design and conclusions. First, the study based its conclusions on 13 patients with ovarian cancer , 12 who had taken fertility enhancing medications and 1 who had not. The 12 affected patients were the only patients with ovarian cancer ...

The American Cancer Society pre- dicts that in 2003, about 25,400 new cases of ovarian cancer will be diagnosed and 14,300 women will die of the disease. Among U.S. women, ovarian cancer is the sev- enth most common cancer and the fifth leading cause of cancer death after lung and bronchus, breast, col- orectal, and pancreatic cancers. Ovarian cancer causes more deaths than any other type of gynecologic cancer and accounts for 5% of all cancer deaths among women. Although the U.S. incidence rate has changed little since 1973, the mor- tality rate has decreased by about 12%. In 1999, the age-adjusted inci- dence rate for white women—17.6 cancers per 100,000 women—was higher than the corresponding rates for Asians/Pacific Islanders (13.1), Hispanics (12.0), and blacks (11.8). The Burden of Ovarian Cancer ...

Initial Legislation Important to the Ovarian Cancer Community in the 108 th Congress I. Research Appropriations Department of Defense Ovarian Cancer Research Program (OCRP) Modeled after the very successful breast cancer research program first included in the DOD budget in 1992, the OCRP is a component of the DoD Congressional Special Interest Research Program. The overall goal of the OCRP is to promote innovative research that will lead to a better understanding and control of ovarian cancer . This program has funded major research leading to a significant strengthening of the ovarian cancer research effort. This year the Ovarian Cancer Research Program is funded at $10 million, up from $7.5 in 1997 when the program began, but down from $12 million in 2001. Status: The House and Senate Defense Appropriations ...

Ovarian Cancer WHAT IS OVARIAN CANCER ? The ovaries are two small, almond-shaped organs located on either side of the uterus (the hollow muscular organ, commonly called the womb, in which the fetus develops). They are key components of a woman's reproductive system: Ovaries store between 200,000 and 400,000 follicles, tiny sacs, present from birth, that nurture immature eggs, or ova. • During each normal (usually monthly) reproductive cycle, a follicle in one ovary bursts and releases a mature or "ripened" egg. The egg travels down the fallopian tube into the uterus, where it either is fertilized by a man's sperm or, if unfertilized, breaks down and is excreted as part of the menstrual cycle. • Ovaries also secrete the important reproductive hormones estrogen and progesterone. • Ovarian Cancers Ovarian cancers are potentially life-threatening ...

Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 CANCER (Supplement) 2003(May15);97/10:2615-2706. Descriptive Epidemiology of Ovarian Cancer in the United States, 1992-1997 Marc T. Goodman and Holly L. Howe Ovarian cancer is relatively uncommon, and therefore little has been published to date regarding racial or ethnic variations in the incidence or mortality of this malignancy. As the U.S. population becomes more diverse, the interest in health problems and disparities in outcomes among minority and economically disadvantaged groups will continue to increase. In this supplement, the authors focus on epidemiology, pathology and classification issues, multiple primary tumors, staging, and incidence and mortality for race/ethnic groups. The authors also focused on epidemiologic differences between borderline tumors of low malignant potential and ...

Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells Marijke Kamsteeg 1 , Thomas Rutherford 1 , Eva Sapi 1 , Bozena Hanczaruk 1 , Shoreh Shahabi 1 , Maryann Flick 1 , David Brown 1,2 and Gil Mor* ,1 1 Department of Obstetrics and Gynecology, Yale University, School of Medicine, New Haven, CT, USA Interference with the innate apoptotic activity is a hallmark of neoplastic transformation and tumor forma- tion. In this study we characterize the cytotoxic effect of phenoxodiol, a synthetic anticancer drug analog of genestein, and demonstrate the mechanism of action by which phenoxodiol affects the components of the Fas apoptotic pathway on ovarian cancer cells. Primary ovarian cancer cells, isolated from ...

‘DARE TO DREAM’ for Ovarian Cancer Deborah Landry rides across Canada to create awareness and support for Ovarian Cancer women – coming to your community !! June 14 th – September 6 th , 2003 For further information: www.daretodreamforovariancancer.ca Sandi Pniauskas Sara Grech Spokesperson/Communications Coordinator/Sponsorship Fundraising 905 668-0767 905 668-8735 sandipn@sympatico.ca saraovarian@hotmail.com Communities along the 17,765 km that DEBORAH will be visiting along with your Ovarian Cancer Survivors, Families, Friends and their participating Doctors and Cancer Centres TORONTO, OSHAWA, KINGSTON, MONTREAL, EDMUNSTON, FREDERICTON, SUMMERSIDE, BELLE RIVER, PICTOU, HALIFAX, PORT HAWKESBURY, BADDECK, ...

Screening for Ovarian Cancer C H A P T E R 72 By Cindy Quinton Gladstone Page 2 Screening for Ovarian Cancer 72 Prepared by Cindy Quinton Gladstone, MHSc, MD, FRCPC 1 O varian cancer is the leading cause of gynecologic cancer mortality in North America. The disease has usually spread beyond the ovary by the time of diagnosis, and is associated with a five-year survival of 35% or less, as compared with 90% for Stage I tumours. To date, standard treatments have had little impact on mortality, and attention has focused on early detection through screening. A review of the evidence does not support such action. In fact, given the poor positive predictive value of pelvic examination, abdominal and transvaginal sonography, ...

Screening for Ovarian Cancer Why may screening for ovarian cancer be important? Early stage ovarian cancer confined to the ovaries (stage I) has an extremely good outlook and can be successfully treated. Unfortunately most ovarian cancers are not recognised at an early stage for a number of reasons. First, cancer of the ovary usually develops after the menopause when the ovaries are inactive and abnormal function of the ovary is not therefore readily noticed. Second, the ovaries are located deep inside the pelvis and are inaccessible to examination. Finally, even when symptoms do occur they are usually vague, non-specific symptoms which could be due to a host of other causes. For these reasons by the time most women with ovarian cancer develop symptoms and their cancer is detected it has spread outside ...

Revised 3/4/02 C/Ke documents/ /Patient Info on Fertility Drugs and Ovarian Cancer Kutteh Ke Fertility Associates of Memphis, PLLC 80 Humphreys Center, Suite 307 Memphis, TN 38120 T: 901.747.2229 F: 901.747.4446 www.fertilitymemphis.com Patient Fact Sheet Infertility, Fertility Drugs, and Ovarian Cancer Many couples faced with infertility are treated with ovulation induction medications, often referred to as fertility drugs. These medications (such as clomiphene citrate) may help a patient to ovulate who previously was not ovulating or, when given empirically, may induce one or two more follicles to be produced each cycle than the customary one. The second class of fertility drugs (gonadotropins) are usually given as some form of an injection and will induce the timed release of multiple eggs in one cycle. These medications are commonly ...